Astrana Health initiated with an Outperform at Baird

Baird initiated coverage of Astrana Health with an Outperform rating and $54 price target. The firm started coverage on three Value Based Care companies, stating that while Value Based Care has recently taken “a small step back” because of regulatory headwinds in Medicare Advantage, it believes the sector will be “ready to take a giant leap forward in the coming years.”